The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
 
Vanesa Gregorc
No Relationships to Disclose
 
Maria González-Cao
Honoraria - BeiGene Beijing; BMS Spain; MSD Oncology; Pierre Fabre; Sanofi
Speakers' Bureau - BMS Spain; MSD Oncology
Research Funding - AstraZeneca; Roche
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology
 
Stefania Salvagni
No Relationships to Disclose
 
Anna Koumarianou
Honoraria - Merck; Pfizer
Consulting or Advisory Role - Ipsen; Novartis
Travel, Accommodations, Expenses - Genesis Pharma; Roche
 
Ignacio Gil-Bazo
Employment - Fundación Instituto Valenciano de Oncología
Consulting or Advisory Role - Boehringer Ingelheim; Janssen; MSD; Seagen
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Janssen; MSD; Seagen
Travel, Accommodations, Expenses - Janssen; MSD; Sanofi
 
Michele Maio
Stock and Other Ownership Interests - Epigen Therapeutics; Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
 
Santiago Viteri
No Relationships to Disclose
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche
 
Vanesa Gutiérrez
No Relationships to Disclose
 
Reyes Bernabe Caro
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; MSD Oncology; Roche; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Miguel F. Sanmamed
No Relationships to Disclose
 
Huaqiang Zhu
Employment - GenFleet Therapeutics
Stock and Other Ownership Interests - Genfleet Therapeutics
 
Haige Shen
Employment - Genfleet Therapeutics
Stock and Other Ownership Interests - Genfleet Therapeutics; Laekna Therapeutics
 
Yu Wang
Employment - GenFleet Therapeutics
Stock and Other Ownership Interests - Genfleet Therapeutics
 
Rafael Rosell
Consulting or Advisory Role - Blueprint Medicines; Merck KGaA